Roche, which put billions on the line a year ago across several ADC pacts, has returned to Innovent Biologics—this time delving into the China-based biopharma’s pipeline for IBI3009 ...

Roche unveiled plans to sell the site in May ... making it one of the largest biologics manufacturing sites worldwide by volume, Lonza said. "The Vacaville site is a highly valuable strategic ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

May 31 (Reuters) - (This May 31 story has been corrected to fix the spelling of executive's name to Teresa, not Theresa, in paragraph 5) Swiss drugmaker Roche Holding AG (ROG.S), opens new tab ...

Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar of Roche's bevacizumab for intravenous use.

Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division. The deal, due to close in the second half ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Innovent Biologics has entered into an exclusive global license ...

Roche's biologics focus and innovative pipeline are key to the firm's ability to maintain its wide moat and continue to achieve growth as current blockbusters face competition. Blockbuster cancer ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC ...

The FDA has accepted Roche’s supplemental Biologics License Application (sBLA) for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for treating relapsed or refractory (R/R ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Innovent Biologics (HK:1801 ... Innovent Biologics has entered into an exclusive global license agreement with Roche for the development and commercialization of its novel DLL3-targeted antibody ...